Brand Name

Triptodur

Generic Name
Triptorelin
View Brand Information
FDA approval date: September 08, 2017
Form: Kit

What is Triptodur (Triptorelin)?

TRIPTODUR is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty . TRIPTODUR is a gonadotropin releasing hormone agonist indicated for the treatment of pediatric patients 2 years and older with central precocious puberty.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Copenhagen Menopause Study (COMPASS): A Randomized Clinical Trial
Copenhagen Menopause Study (COMPASS): A Randomized Clinical Trial
Enrollment Status: Recruiting
Publish Date: December 11, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to bone Loss and other complications. Estrogen therapy can help, but some women avoid it due to the increased risk of blood clots and cancer. This project will investigate whether blocking LH could offer a safe alternative to alleviate symptoms...

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
Enrollment Status: Recruiting
Publish Date: December 02, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (...

A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
Enrollment Status: Recruiting
Publish Date: November 18, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: PREcoopERA is a randomized (2:2:1), multicenter, open-label, three-arm (A, B, C), Window-of-Opportunity (WOO) trial to evaluate the activity and safety of giredestrant (A) versus giredestrant plus triptorelin (B) versus anastrozole plus triptorelin (C).

View All Clinical Trials

Related Latest Advances

Triptorelin: The Need for Legal Protection Aimed at the Full Political and Social Integration of Gender Variant youth. A Comparison of Different Global realities.
Triptorelin: The Need for Legal Protection Aimed at the Full Political and Social Integration of Gender Variant youth. A Comparison of Different Global realities.
Journal: La Clinica terapeutica
Published: November 21, 2025
Racial Differences in Adverse Events After Androgen Deprivation in Veterans With Prostate Cancer.
Racial Differences in Adverse Events After Androgen Deprivation in Veterans With Prostate Cancer.
Journal: JAMA network open
Published: November 19, 2025
Tales from the clinic: A case of congenital long QT syndrome and medically induced menopause.
Tales from the clinic: A case of congenital long QT syndrome and medically induced menopause.
Journal: Post reproductive health
Published: November 14, 2025
View All Latest Advances